



Sanofi appoints David Loew, Senior Vice President, Commercial Operations, Europe

Paris, France - May 23, 2013 - Sanofi (EURONEXT : SAN and NYSE : SNY) is pleased to announce today the appointment of David Loew, as Senior Vice President, Commercial Operations, Europe, effective July 1st, 2013. He will report to Peter Guenter in his new role as Executive Vice President, Global Commercial Operations. David will join the Global Leadership Team and become Chairman of the European Strategic Committee.

As Senior Vice President, Commercial Operations, Europe, David Loew will be responsible for 38 countries organized into direct countries and Multi Country Organizations. David will be responsible for defining the commercial strategy for the region and lead its effective execution through more than 9,000 employees.

Peter Guenter, currently Senior Vice President, Europe, Sanofi declared:

“Europe remains a key strategic region for Sanofi, with a high level of complexity and diversity of markets, facing critical challenges in a mature environment. David’s vast experience, international exposure and know how at both country and corporate positions will be a significant addition to Sanofi and make him ideally suited to lead our commercial operations in Europe.”

David Loew will join Sanofi from Roche Pharmaceuticals where he is currently Regional Head Eastern Europe, Middle East and Africa.

Biography of David Loew

Swiss born, David Loew, started his career with traineeships in the US at Coopers & Lybrand and Hewlett Packard in 1990, before joining Roche in 1992 as a sales representative in Vienna, Austria. He moved to Basel in 1993 for a management development programme and then took up the position of Senior Product Manager in France in 1995. Within two years, David was promoted to Marketing Manager for transplantation and dialysis. In 1999 he was appointed Business Director, Specialty Care in Mexico.

David was promoted in 2001 to global marketing roles - “Life Cycle Leader” - of growing importance, splitting his time between Nutley, New Jersey and Basel, Switzerland. He was instrumental in developing and launching several indications of Xeloda and MabThera shaping the drugs successes. Subsequently David took over the position as Oncology head.

After six years in marketing roles, David became General Manager Switzerland in 2007 and at the beginning of 2010, was appointed Global Chief Marketing Officer / Head of Global Product Strategy for the pharmaceuticals division of Roche. His remit included the responsibility for all therapeutic areas of Roche, including the area heads, life cycle and global brand teams, the global medical affairs function, global pharmaceuticals economics and pricing. In early 2013, he was appointed to his current role as Regional Head Eastern Europe, Middle East and Africa.

David has a degree in Finance and Marketing and an MBA from the University of St. Gallen (HSG). German is David’s native tongue and he speaks English, French and Spanish fluently.



About Sanofi

Sanofi, an integrated global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi has core strengths in the field of healthcare with seven growth platforms: diabetes solutions, human vaccines, innovative drugs, consumer healthcare, emerging markets, animal health and the new Genzyme. Sanofi is listed in Paris (EURONEXT: SAN) and in New York (NYSE: SNY).

Forward Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These statements include projections and estimates and their underlying assumptions, statements regarding plans, objectives, intentions and expectations with respect to future financial results, events, operations, services, product development and potential, and statements regarding future performance. Forward-looking statements are generally identified by the words "expects", "anticipates", "believes", "intends", "estimates", "plans" and similar expressions. Although Sanofi's management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Sanofi, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2012. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Contacts:

Media Relations

Jean-Marc Podvin
Tel.: + (33) 1 53 77 46 46
mr@sanofi.com

Investor Relations

Sébastien Martel
Tel.: + (33) 1 53 77 45 45
ir@sanofi.com